Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...

44 Since the RAC does not distinguish whether pancreatic fluid collections require interventional drainage, the majority of RAC II patients had a relatively mild course of disease with organ failure ...